David Arpon
Princess Alexandra Hospital
4 Papers
8 Citations
David Arpon is an academic researcher from Princess Alexandra Hospital. The author has contributed to research in topics: CD163 & Diffuse large B-cell lymphoma. The author has an hindex of 2, co-authored 4 publications. Previous affiliations of David Arpon include Translational Research Institute & University of Queensland.
Chat about Author
Papers
Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL
Frank Vari,David Arpon,Colm Keane,Colm Keane,Mark Hertzberg,Dipti Talaulikar,Dipti Talaulikar,Sanjiv Jain,Qingyan Cui,Erica Han,Josh Tobin,Josh Tobin,Robert Bird,Donna Cross,Annette Hernandez,Clare Gould,Clare Gould,Simone Birch,Maher K. Gandhi,Maher K. Gandhi +19 more
TL;DR: A hitherto unrecognized immune evasion strategy mediated via skewing toward an exhausted PD-1-enriched CD3-CD56hiCD16-ve NK-cell phenotype is described, which can occur indirectly by PD-L1/PD-L2-expressing TAMs and contribute to the clinical sensitivity of cHL toPD-1 blockade.
283
The Pandora's box of novel technologies that may revolutionize lung cancer.
Habib Sadeghi Rad,Hamid Sadeghi Rad,Yavar Shiravand,Payar Radfar,David Arpon,Majid Ebrahimi Warkiani,Kenneth J. O'Byrne,Arutha Kulasinghe +7 more
TL;DR: In this article, the authors reviewed the recent advancements in spatial profiling technologies for the analysis of NSCLC tissue samples to gain new insights and therapeutic options for non-small cell lung cancer (NSCLC) patients.
15
A new frontier in haematology – combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug
David Arpon,David Arpon,Maher K. Gandhi,Maher K. Gandhi,Jennifer H. Martin,Jennifer H. Martin +5 more
TL;DR: In this paper, the clinical potential for combined pharmacokinetically and pharmacodynamically guided dosing of new targeted agents in haematological malignancies is discussed. But, the evidence to support the behaviour is minimal, particularly when long-term outcomes are considered.
9
A Novel Anti-Lymphoma Immune Evasion Mediated By the Interaction Between PD-1 Enriched NK-Cells and CD163+PD-L1+PD-L2+ Tumor Associated Macrophages, That Is More Prominent in Hodgkin Lymphoma Than Diffuse Large B-Cell Lymphoma
Maher K. Gandhi,Maher K. Gandhi,David Arpon,Colm Keane,Colm Keane,Erica Han,Josh Tobin,Josh Tobin,Robert Bird,Mark Hertzberg,Marlene Self,Donna Cross,Annette Hernandez,Frank Vari +13 more
TL;DR: A hitherto unrecognised immune evasion strategy mediated via skewing towards an exhausted PD-1 enriched CD16-CD56hiCD3- NK-cell phenotype is described, which enhances the sensitivity of PD-L1/PD-L2 to NK-cells and inhibitory CD163+ expressing monocytes/macrophages in the setting of HL and DLBCL.
2